Document Detail


Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction.
MedLine Citation:
PMID:  8504497     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Staphylokinase (STA), a protein with known profibrinolytic properties, is produced by transduced Staphylococcus aureus strains. In experimental animal models, recombinant staphylokinase (STAR) is less immunogenic and more active toward platelet-rich arterial blood clots than streptokinase. METHODS AND RESULTS: In the present study, 10 mg STAR given intravenously over 30 minutes was found to induce angiographically documented coronary artery recanalization within 40 minutes in four of five patients with acute myocardial infarction. Plasma fibrinogen and alpha 2-antiplasmin levels were unaffected, and allergic reactions were not observed. Postinfusion disappearance of STAR antigen followed a biphasic mode with a t1/2 alpha of 6.3 +/- 0.6 minutes (mean +/- SD) and a t1/2 beta of 37 +/- 15 minutes, corresponding to a plasma clearance of 270 +/- 100 mL/min. Neutralizing antibodies against STAR could not be demonstrated at baseline and up to 6 days after infusion, but STAR neutralizing activity, which did not cross-react with streptokinase, was consistently demonstrable in plasma at 14-35 days. CONCLUSIONS: STAR can induce clot-selective coronary thrombolysis in patients with evolving myocardial infarction without concomitant induction of a systemic lytic state. STAR, a small protein that can be easily produced by recombinant DNA technology, may therefore offer promise for thrombolytic therapy in patients with thromboembolic disease.
Authors:
D Collen; F Van de Werf
Related Documents :
2868337 - Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. gru...
3315587 - Anisoylated plasminogen streptokinase activator complex versus streptokinase in acute m...
8159597 - Febrile reaction associated with urokinase.
3717017 - High-dose, brief-duration intravenous infusion of streptokinase in acute myocardial inf...
24424157 - Remote ischaemic conditioning and ischaemic heart disease.
3669277 - Prognosis of dilated cardiomyopathy: from a retrospective to a prospective study employ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Circulation     Volume:  87     ISSN:  0009-7322     ISO Abbreviation:  Circulation     Publication Date:  1993 Jun 
Date Detail:
Created Date:  1993-07-02     Completed Date:  1993-07-02     Revised Date:  2010-03-24    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1850-3     Citation Subset:  AIM; IM    
Affiliation:
Center for Thrombosis and Vascular Research, University of Leuven, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Coronary Angiography
Coronary Vessels / physiopathology
Female
Humans
Male
Metalloendopeptidases / pharmacokinetics,  therapeutic use*
Middle Aged
Myocardial Infarction / drug therapy*,  radiography
Pilot Projects
Recombinant Proteins / pharmacokinetics,  therapeutic use
Thrombolytic Therapy*
Time Factors
Vascular Patency / physiology
Chemical
Reg. No./Substance:
0/Recombinant Proteins; EC 3.4.24.-/Metalloendopeptidases; EC 3.4.24.29/auR protein, Staphylococcus aureus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Myocardial infarct size can be estimated from serial plasma myoglobin measurements within 4 hours of...
Next Document:  X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dyst...